Amitriptyline Inhibits Nonalcoholic Steatohepatitis and Atherosclerosis Induced by High-Fat Diet and LPS through Modulation of Sphingolipid Metabolism.

We reported previously that increased acid sphingomyelinase (ASMase)-catalyzed hydrolysis of sphingomyelin, which leads to increases in ceramide and sphingosine 1 phosphate (S1P), played a key role in the synergistic upregulation of proinflammatory cytokines by palmitic acid (PA), a major saturated fatty acid (SFA), and lipopolysaccharide (LPS) in macrophages. Since macrophages are vital players in nonalcoholic steatohepatitis (NASH) and atherosclerosis, we assessed the effect of ASMase inhibition on NASH and atherosclerosis cooperatively induced by high PA-containing high-fat diet (HP-HFD) and LPS in LDL receptor-deficient (LDLR-/-) mice. LDLR-/- mice were fed HP-HFD, injected with low dose of LPS, and treated with or without ASMase inhibitor amitriptyline. Neutral sphingomyelinase inhibitor GW4869 was used as control. Metabolic study showed that both amitriptyline and GW4869 reduced glucose, lipids and insulin resistance. Histological analysis and Oil Red O staining showed that amitriptyline robustly reduced hepatic steatosis while GW4869 had modest effects. Interestingly, immunohistochemical study showed that amitriptyline, but not GW4869, strongly reduced hepatic inflammation. Furthermore, results showed that both amitriptyline and GW4869 attenuated atherosclerosis. To elucidate the underlying mechanisms whereby amitriptyline inhibited both NASH and atherosclerosis, but GW4869 only inhibited atherosclerosis, we found that amitriptyline, but not GW4869, downregulated proinflammatory cytokines in macrophages. Finally, we found that inhibition of S1P production is a potential mechanism whereby amitriptyline inhibited proinflammatory cytokines. Collectively, this study showed that amitriptyline inhibited NASH and atherosclerosis through modulation of sphingolipid metabolism in LDLR-/- Mice and indicated that sphingolipid metabolism in macrophages plays a crucial role in the linkage of NASH and atherosclerosis.

[1]  V. Nomellini,et al.  Amitriptyline Treatment Mitigates Sepsis-Induced Tumor Necrosis Factor Expression and Coagulopathy , 2019, Shock.

[2]  T. Lyons,et al.  Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro. , 2018, American journal of physiology. Endocrinology and metabolism.

[3]  S. Taylor-Robinson,et al.  Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. , 2018, Diabetes research and clinical practice.

[4]  Junfei Jin,et al.  LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages , 2018, Journal of leukocyte biology.

[5]  W. Zin,et al.  The role of sphingolipid metabolism disruption on lipopolysaccharide-induced lung injury in mice. , 2018, Pulmonary Pharmacology & Therapeutics.

[6]  A. Nègre-Salvayre,et al.  nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe−/− Mice , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[7]  E. Gulbins,et al.  Regulation of Arthritis Severity by the Acid Sphingomyelinase , 2017, Cellular Physiology and Biochemistry.

[8]  M. Lopes-Virella,et al.  Cooperative stimulation of atherogenesis by lipopolysaccharide and palmitic acid-rich high fat diet in low-density lipoprotein receptor-deficient mice. , 2017, Atherosclerosis.

[9]  J. M. G. Gomes,et al.  Metabolic endotoxemia and diabetes mellitus: A systematic review. , 2017, Metabolism: clinical and experimental.

[10]  K. Kowdley,et al.  The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. , 2016, Clinics in liver disease.

[11]  M. Lopes-Virella,et al.  TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes. , 2015, Immunobiology.

[12]  Y. Hannun,et al.  GPR40/FFA1 and neutral sphingomyelinase are involved in palmitate-boosted inflammatory response of microvascular endothelial cells to LPS. , 2015, Atherosclerosis.

[13]  Yan Huang,et al.  Metabolic Syndrome Exacerbates Inflammation and Bone Loss in Periodontitis , 2015, Journal of dental research.

[14]  T. Pritts,et al.  Acid sphingomyelinase inhibition protects mice from lung edema and lethal Staphylococcus aureus sepsis , 2015, Journal of Molecular Medicine.

[15]  C. Trautwein,et al.  ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis. , 2014, Journal of hepatology.

[16]  I. Jialal,et al.  Endotoxemia of metabolic syndrome: a pivotal mediator of meta-inflammation. , 2014, Metabolic syndrome and related disorders.

[17]  S. Subramanian,et al.  The Apolipoprotein-AI Mimetic Peptide L4F at a Modest Dose Does Not Attenuate Weight Gain, Inflammation, or Atherosclerosis in LDLR-Null Mice , 2014, PloS one.

[18]  Wenfeng Zhang,et al.  Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. , 2014, Annals of hepatology.

[19]  Y. Hannun,et al.  Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages. , 2013, American journal of physiology. Endocrinology and metabolism.

[20]  K. Moore,et al.  Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.

[21]  M. Chonchol,et al.  Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. , 2013, Current pharmaceutical design.

[22]  E. Seki,et al.  Toll‐like receptors in alcoholic liver disease, non‐alcoholic steatohepatitis and carcinogenesis , 2013, Journal of gastroenterology and hepatology.

[23]  J. Kornhuber,et al.  Acid sphingomyelinase–ceramide system mediates effects of antidepressant drugs , 2013, Nature Medicine.

[24]  M. Hofker,et al.  NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. , 2012, Atherosclerosis.

[25]  J. Shelhamer,et al.  A Cytosolic Phospholipase A2-Initiated Lipid Mediator Pathway Induces Autophagy in Macrophages , 2011, The Journal of Immunology.

[26]  E. Poggiogalle,et al.  Management of metabolic syndrome in children and adolescents. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[27]  P. Hayes,et al.  Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study , 2011, Diabetes Care.

[28]  M. Véniant,et al.  A Volumetric Method for Quantifying Atherosclerosis in Mice by Using MicroCT: Comparison to En Face , 2011, PloS one.

[29]  J. Boyle,et al.  The Alternative Pathway Is Critical for Pathogenic Complement Activation in Endotoxin- and Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice , 2010, Circulation.

[30]  K. Boini,et al.  Role of Sphingolipid Mediator Ceramide in Obesity and Renal Injury in Mice Fed a High-Fat Diet , 2010, Journal of Pharmacology and Experimental Therapeutics.

[31]  Milton Waner,et al.  Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic β-like cells , 2010, Proceedings of the National Academy of Sciences.

[32]  Y. Hannun,et al.  The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. , 2010, Current molecular medicine.

[33]  G. Svegliati-Baroni,et al.  From the metabolic syndrome to NAFLD or vice versa? , 2010, Digestive and Liver Disease.

[34]  Sabine Borwege,et al.  Nutrient Modification of the Innate Immune Response: A Novel Mechanism by Which Saturated Fatty Acids Greatly Amplify Monocyte Inflammation , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[35]  E. Gulbins,et al.  Therapeutic Efficacy and Safety of Amitriptyline in Patients with Cystic Fibrosis , 2009, Cellular Physiology and Biochemistry.

[36]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  H. Tilg,et al.  Insulin resistance, inflammation, and non-alcoholic fatty liver disease , 2008, Trends in Endocrinology & Metabolism.

[38]  M. Weller,et al.  Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis , 2008, Nature Medicine.

[39]  J. Romijn,et al.  Apolipoprotein C-I Is Crucially Involved in Lipopolysaccharide-Induced Atherosclerosis Development in Apolipoprotein E-Knockout Mice , 2007, Circulation.

[40]  K. Qureshi,et al.  Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. , 2007, World journal of gastroenterology.

[41]  E. Schuchman,et al.  The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann–Pick disease , 2007, Journal of Inherited Metabolic Disease.

[42]  J. Ferrières,et al.  Metabolic Endotoxemia Initiates Obesity and Insulin Resistance , 2007, Diabetes.

[43]  S Kumar,et al.  Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[44]  I. Heuser,et al.  Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. , 2006, The Journal of clinical psychiatry.

[45]  J. Kornhuber,et al.  High activity of acid sphingomyelinase in major depression , 2005, Journal of Neural Transmission.

[46]  D. Pickens,et al.  Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome , 2005, Gut.

[47]  P. Ganz,et al.  Role of Endothelial Dysfunction in Atherosclerosis , 2004, Circulation.

[48]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[49]  Yusuf A. Hannun,et al.  The Ceramide-centric Universe of Lipid-mediated Cell Regulation: Stress Encounters of the Lipid Kind* , 2002, The Journal of Biological Chemistry.

[50]  T. Martin,et al.  Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .

[51]  R. Bell,et al.  Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cells. , 1988, Biochimica et biophysica acta.

[52]  T. Lyons,et al.  Interaction of palmitate and LPS regulates cytokine expression and apoptosis through sphingolipids in human retinal microvascular endothelial cells , 2019, Experimental eye research.

[53]  Michael Roden,et al.  NAFLD and diabetes mellitus , 2017, Nature Reviews Gastroenterology &Hepatology.

[54]  G. Cascio,et al.  Dietary fatty acids in metabolic syndrome, diabetes and cardiovascular diseases. , 2012, Current diabetes reviews.

[55]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[56]  M. Hofker,et al.  Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice , 2005, Clinical chemistry and laboratory medicine.

[57]  S. Gordon,et al.  F4/80, a monoclonal antibody directed specifically against the mouse macrophage , 1981, European journal of immunology.